Open navigation menu
Invest
Invest on your own
We do it for you
Halal tools
Screeners
Your portfolio
Calculators
Shariah
Our certifications
Learn
Education
Get help
News
Pricing
Company
About Musaffa
Investors
Build with us
Is Brainstorm Cell Therapeutics Inc Stock Halal?
Shariah Compliance Analysis of BCLI Stock
No. As of October 2026, Brainstorm Cell Therapeutics Inc (BCLI) is classified as NOT HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. Brainstorm Cell Therapeutics Inc does not pass Musaffa's business and financial screening criteria.
Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. The company is headquartered in New York City, New York and currently employs 20 full-time employees. The company went IPO on 2003-05-28. The firm is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The firm's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.
BCLI Shariah Compliance
Screening Methodology: AAOIFI
As of October 2026, Brainstorm Cell Therapeutics Inc is classified as not halal.
NOT HALALBrainstorm Cell Therapeutics Inc (BCLI) Chart
Fetching Price Chart...
Financial Metrics & Statements of Brainstorm Cell Therapeutics Inc (BCLI)
FAQ's for Brainstorm Cell Therapeutics Inc (BCLI)
- As of October 2026, Brainstorm Cell Therapeutics Inc BCLI is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Brainstorm Cell Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Brainstorm Cell Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Brainstorm Cell Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Brainstorm Cell Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Brainstorm Cell Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Brainstorm Cell Therapeutics Inc (BCLI)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.